Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct
Mandate

Vinge acts for EQT and the subsidiary company ESML Intressenter in connection with the takeover bid for Securitas Direct

November 13, 2007

Vinge is acting for EQT and the subsidiary company, jointly owned by EQT, SäkI AB, Melker Schörling AB and Investment AB Latour, in connection with the public cash offer to the shareholders of Securitas Direct AB. The offer also includes an offer to the holders of subscription options in Securitas Direct AB. Securitas Direct AB is listed on the OMX Nordic Stock Exchange. Vinge assists with stock exchange and corporate advice, financing, and acquisition structuring. The total value of the offer is appr. 9.6 billion kronor.

The Vinge team includes Hans Wibom, Michael Wigge, Ola Sandersson, Christoffer Saidac, Tuula Tallavaara, Dain Nevonen and Martin Hall. Fabian Ekeblad and Louise Salomon assist with the financing and Johan Karlsson and Peter Forsberg assist with the competition filing.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024